ORYZON reports financial results and corporate update for quarter ended March 31st, 2026
Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended March 31, 2026, and provided a corporate update on recent developments.
“During the first months of 2026, Oryzon has continued to execute strongly across both its oncology/hematology and CNS franchises, while maintaining a solid financial position,” said Dr. Carlos Buesa, Oryzon’s Chief Executive Officer. “Most importantly, iadademstat continues to deliver highly encouraging clinical data in acute myeloid leukemia, further reinforcing our conviction in the compound’s differentiated therapeutic potential and commercial opportunity.”
“We are particularly excited about the upcoming presentations at EHA 2026, where updated safety and efficacy results from both the ALICE-2 and FRIDA studies will be presented,” Dr. Buesa added. “In first-line AML, the triplet combination of iadademstat with azacitidine and venetoclax continues to demonstrate a highly competitive efficacy profile, which we believe compares very favorably with other emerging triplet regimens in the field. At EHA, we will present updated data from 18 patients, including encouraging activity in patients with adverse genetic backgrounds. Based on the progress achieved to date, we believe iadademstat-based combinations may offer a differentiated and competitive opportunity for accelerated clinical development in first-line AML and could support advancement into a potentially pivotal Phase II/III program with the objective of pursuing accelerated regulatory approval.”
“The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,” Dr. Buesa continued. ”Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, emerging opportunities in non-malignant hematology, including sickle cell disease and essential thrombocythemia, could materially enlarge the commercial and strategic scope of the franchise. Taken together, we believe iadademstat will deliver increasingly diversified clinical catalysts and generate sustained data, supporting a strong cadence of newsflow over the coming quarters.”
“In CNS, we remain fully committed to advancing vafidemstat toward late-stage development,” continued Dr. Buesa. “We continue to work closely on the activities required to support the Phase III PORTICO-2 protocol resubmission following FDA feedback, while also advancing the EVOLUTION schizophrenia study and preparations for the new HOPE-2 study in autism spectrum disorder. We believe vafidemstat continues to represent an important long-term value driver for Oryzon.”
See all the details in the attached press release.